Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

NIH 7OTHER 5INDUSTRY 3NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 3Tumor-Agnostic 1Thoracic 1

Conditions

Fallopian Tube Neoplasms 2Uterine Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 593Cyclophosphamide 539Magnetic Resonance Spectroscopy 527Radiotherapy 506Specimen Handling 504Nivolumab 406Cisplatin 370Carboplatin 360Biopsy 306Blood Specimen Collection 296Radiosurgery 284Paclitaxel 276Surveys and Questionnaires 269Standard of Care 267Gemcitabine 266fludarabine 261Dexamethasone 258Drug Therapy 256Bevacizumab 248venetoclax 247Oxaliplatin 206Rituximab 197Capecitabine 194Radiation 190Fluorouracil 186Ipilimumab 183durvalumab 181Doxorubicin 174atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × adavosertib × 1 year × Clear all
NCT02659241 2026-04-15

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
38 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms

NCT02513563 2026-02-19

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
42 enrolled 12 charts
Thoracic

Lung Neoplasms

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
96 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT03668340 2026-01-12

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
49 enrolled
Gynecologic

Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡